Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening

Abstract Background Bladder cancer (BLC) remains a clinically challenging malignancy due to its pronounced inter- and intra-patient heterogeneity, which contributes to therapeutic resistance and poor clinical outcomes. Capturing and modeling this complexity is essential for the development of effect...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Carlotta Frascolla, Riccardo Mastroianni, Catarina Macedo-Silva, Marta De Menna, Giulia Orlandi, Daniela Angela Covino, Martina Minoli, Martina Radic, Federico La Manna, Claudio Pulito, Sebastiano Vaccarella, Frauke Goeman, Ludovica Ciuffreda, Matteo Allegretti, Roland Seiler, Bernhard Kiss, Valentina De Pascale, Federica Runci, Fabio Calabrò, Yaron Vinik, Sima Lev, Sabrina Strano, Maurizio Fanciulli, Brindusa Ana Maria Arteni, Simona Di Martino, Andrea Russo, Sara Donzelli, Marianna Kruithof-de Julio, Giovanni Blandino, Giuseppe Simone
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-04-01
Colecção:	Journal of Experimental & Clinical Cancer Research
Assuntos:	Bladder cancer Patient-derived organoids (PDOs) Tumor microenvironment (TME) Immune preservation Immunotherapy Spatial heterogeneity
Acesso em linha:	https://doi.org/10.1186/s13046-026-03701-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!